9th Nov 2020 10:01
(Alliance News) - FTSE 250-listed Oxford BioMedica PLC on Monday said it is collaborating with UK biopharmaceutical company PhoreMost Ltd to develop next-generation CAR-T cell therapies.
CAR-T therapy, or chimeric antigen receptor T-cell therapy, is specifically developed for each individual patient and involves reprogramming the patient's own immune system cells which are then used to target their cancer.
The gene and cell therapy group stated that under the collaboration, PhoreMost will use its phenotypic screening platform Siteseeker to identify therapeutic candidates for Oxford Biomedica's LentiVector gene therapy delivery system. It added the programme will initially focus on CAR-T therapy and will aim to develop next-generation cell therapies with significantly-improved efficacy and durability.
"We are excited to apply this next-generation technology to our LentiVector platform. The collaboration has the potential to deliver more effective CAR-T therapies, and we look forward to working closely with the PhoreMost team," said Oxford BioMedica Chief Executive John Dawson.
Shares in Oxford BioMedica were trading 0.3% lower at 811.00 pence each on Monday morning in London.
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica